CN117100764A - Composition used before capsule endoscopy - Google Patents
Composition used before capsule endoscopy Download PDFInfo
- Publication number
- CN117100764A CN117100764A CN202311149909.9A CN202311149909A CN117100764A CN 117100764 A CN117100764 A CN 117100764A CN 202311149909 A CN202311149909 A CN 202311149909A CN 117100764 A CN117100764 A CN 117100764A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- mannitol
- composition
- capsule endoscopy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 239000002775 capsule Substances 0.000 title claims abstract description 20
- 238000001839 endoscopy Methods 0.000 title claims abstract description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 43
- 229930195725 Mannitol Natural products 0.000 claims abstract description 43
- 239000000594 mannitol Substances 0.000 claims abstract description 43
- 235000010355 mannitol Nutrition 0.000 claims abstract description 43
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 36
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 34
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 34
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 34
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 28
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 17
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 17
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 17
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 17
- 239000001103 potassium chloride Substances 0.000 claims abstract description 17
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 17
- 239000011780 sodium chloride Substances 0.000 claims abstract description 17
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 16
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 16
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 16
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 16
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 16
- 239000011718 vitamin C Substances 0.000 claims abstract description 16
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 16
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 14
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 206010028813 Nausea Diseases 0.000 claims description 9
- 206010047700 Vomiting Diseases 0.000 claims description 9
- 230000008693 nausea Effects 0.000 claims description 9
- 208000019790 abdominal distention Diseases 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- 239000008141 laxative Substances 0.000 claims description 2
- 229940125722 laxative agent Drugs 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 208000035475 disorder Diseases 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 6
- 206010067484 Adverse reaction Diseases 0.000 abstract description 5
- 230000006838 adverse reaction Effects 0.000 abstract description 5
- 238000004140 cleaning Methods 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000008673 vomiting Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010000060 Abdominal distension Diseases 0.000 description 5
- 206010000059 abdominal discomfort Diseases 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 210000004347 intestinal mucosa Anatomy 0.000 description 5
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010014418 Electrolyte imbalance Diseases 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 230000003749 cleanliness Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000014380 magnesium carbonate Nutrition 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- 208000019025 Hypokalemia Diseases 0.000 description 2
- 206010021027 Hypomagnesaemia Diseases 0.000 description 2
- 206010021036 Hyponatraemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 208000024896 potassium deficiency disease Diseases 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- CDVZCUKHEYPEQS-AZIZVCISSA-N (2r,3s,4s)-2,3,4,5-tetrahydroxypentanal Chemical group OC[C@H](O)[C@H](O)[C@@H](O)C=O.OC[C@H](O)[C@H](O)[C@@H](O)C=O CDVZCUKHEYPEQS-AZIZVCISSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- YTBSYETUWUMLBZ-IMJSIDKUSA-N L-threose Chemical compound OC[C@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IMJSIDKUSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001320 aldopentoses Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
Abstract
The application relates to a composition for preparing intestinal tracts before capsule endoscopy, which comprises the following raw material components in parts by weight: 125-250 parts of mannitol, 30-70 parts of L-arabinose, 1-2 parts of vitamin C, 0.5-1 part of vitamin B6, 0.3-1.2 parts of calcium carbonate, 1-10 parts of potassium chloride, 0.5-5 parts of magnesium carbonate and 2-10 parts of sodium chloride. The application has better intestinal tract preparation effect before capsule endoscopy, less adverse reaction in the taking process, effectively improves the occurrence of electrolyte disorder caused by intestinal tract cleaning medicine, and has good clinical value.
Description
Technical Field
The application relates to the field of medicines, in particular to a composition used before capsule endoscopy.
Background
The gastrointestinal diseases are the countries with higher incidence rate, about 30 percent of people suffer from the gastrointestinal diseases according to relevant epidemiological statistics, since the diagnosis accuracy of the gastrointestinal diseases is greatly improved by the application of the self-digestion endoscope, the currently clinically common digestion endoscopes mainly comprise an electronic gastroscope, an electronic colonoscope, a small intestine endoscope, a capsule endoscope and the like, wherein the capsule endoscope has the advantages of convenient operation, less pain and the like, provides a safe and noninvasive examination means for the examination of the whole digestive tract, and the related research shows that the success rate of the capsule endoscope examination is more than 90 percent, and has good development and application prospect.
Before capsule endoscopy is implemented, intestinal tract preparation is necessary, the feces in the intestinal tract are cleared through various modes, high intestinal tract cleanliness can be obtained through good intestinal tract preparation, and the accuracy of capsule endoscopy can be effectively guaranteed. The ideal intestinal tract preparation method application has the following characteristics: the intestinal tract preparation can empty the excrement in the intestinal tract in a short time, does not cause the change of colon mucous membrane, does not cause the disorder of water electrolyte of patients, has moderate price, but the conventional intestinal tract preparation in clinic at present can not completely meet the above standard, so that it is very important to find a method which meets the characteristics as much as possible.
Mannitol is a clinically common intestinal preparation drug, and can form a hypertonic state in intestinal cavities after oral administration, so that the absorption of water by the intestinal tracts is reduced, the intestinal peristalsis and emptying are stimulated, and related guidelines suggest that mannitol can be used as a diagnostic enteroscope, but mannitol easily causes water electrolyte disorder of patients in the intestinal preparation process, and can cause gastrointestinal discomfort such as nausea, vomiting, abdominal distension and the like.
Therefore, there is a need in the art to develop a medicament that has good bowel cleansing effect and can alleviate symptoms of electrolyte disturbance and gastrointestinal discomfort in patients during bowel preparation.
Disclosure of Invention
The application aims to provide a medicine with good intestine cleaning effect, which can relieve electrolyte disturbance and gastrointestinal discomfort symptoms of patients in the process of preparing the intestinal tract.
The technical scheme of the application is as follows:
the composition for the pre-capsule endoscopy consists of the following raw material components in parts by weight: 125-250 parts of mannitol, 30-70 parts of L-arabinose, 1-2 parts of vitamin C, 0.5-1 part of vitamin B6, 0.3-1.2 parts of calcium carbonate, 1-10 parts of potassium chloride, 0.5-5 parts of magnesium carbonate and 2-10 parts of sodium chloride. Preferably, the material comprises the following raw material components in parts by weight: 150-200 parts of mannitol, 45-60 parts of L-arabinose, 1-2 parts of vitamin C, 0.5-1 part of vitamin B6, 0.6-0.8 part of calcium carbonate, 3-5 parts of potassium chloride, 2-3 parts of magnesium carbonate and 5-6 parts of sodium chloride.
Preferably, the material comprises the following raw material components in parts by weight: 180 parts of mannitol, 49 parts of L-arabinose, 2 parts of vitamin C, 6 1 parts of vitamin B, 0.7 part of calcium carbonate, 4 parts of potassium chloride, 2 parts of magnesium carbonate and 6 parts of sodium chloride.
Preferably, the mannitol is 20% mannitol by mass.
Preferably, the formulation of the composition is a liquid preparation or an oral preparation.
Preferably, for intestinal tract preparation; or as laxatives.
Preferably, also for the prevention and/or treatment of nausea; preventing and/or treating emesis; preventing and/or treating abdominal distention.
The application discovers that mannitol, L-arabinose, vitamin C, vitamin B6, calcium carbonate, potassium chloride, magnesium carbonate and sodium chloride have synergistic cooperation effects on relaxing bowel, promoting intestinal excretion and intestinal preparation when being taken orally, can also improve side effects (electrolyte disorder, nausea, vomiting, abdominal distension and the like) of oral mannitol, and can improve health recovery in the intestinal preparation process of patients.
The application provides a composition, which comprises mannitol, L-arabinose, vitamin C, vitamin B6, calcium carbonate, potassium chloride, magnesium carbonate and sodium chloride.
The mannitol is 20% mannitol, the mannitol is a high-permeability dehydrating agent, and can form a high-permeability state in the intestinal cavity after being orally taken, so that the absorption of water by the intestinal tract is reduced, the liquid is promoted to enter the intestinal cavity, and the peristaltic movement and the evacuation of the intestinal tract are stimulated, so that the aim of cleaning the intestinal tract is fulfilled.
The L-Arabinose is L-Arabinose (L-Arabinose), belongs to aldopentose, is often used as an inducer of a Pbad promoter in an escherichia coli expression system, is also an inhibitor of sucrase, and is proved by researches to promote intestinal peristalsis, relieve constipation, and simultaneously enable the composition to have good taste and relieve discomfort of oral intestinal tract cleaning medicines of patients.
Vitamin C is a water-soluble vitamin, is chemically named as L- (+) -threose type 2,3,4,5, 6-pentahydroxy-2-hexenoic acid-4-lactone, and is also named as L-ascorbic acid, has an antioxidation effect, can effectively maintain the balance of the environment in the intestinal tract, delay the aging and apoptosis of cells, maintain the integrity of the cells and the normal physiological activities of the cells in the preparation process of the intestinal tract, and protect the integrity of intestinal mucosa.
The vitamin B6 is a water-soluble vitamin, also called pyridoxine, which comprises pyridoxine, pyridoxal and pyridoxamine, and the common molecular formula is C8H10NO5P, can exert the effect of maintaining sodium/potassium balance in human body, and can relieve gastrointestinal symptoms such as nausea, vomiting and the like in the process of intestinal tract preparation.
The calcium carbonate is calcium carbonate, so that the loss of calcium ions in the intestinal tract preparation process can be effectively relieved.
The potassium chloride is potassium chloride, so that the loss of potassium ions in the intestinal tract preparation process can be effectively relieved.
The magnesium carbonate is magnesium carbonate, so that the loss of magnesium ions in the intestinal tract preparation process can be effectively relieved.
The sodium chloride is sodium chloride, so that the loss of sodium ions and chloride ions in the intestinal tract preparation process can be effectively relieved.
The main technical effects obtained by the application include:
the oral administration of mannitol, L-arabinose, vitamin C, vitamin B6, calcium carbonate, potassium chloride, magnesium carbonate and sodium chloride can effectively promote the discharge of intestinal excrement, effectively clear the intestinal tract, simultaneously relieve the gastrointestinal reactions such as nausea, vomiting and abdominal distension in the preparation process of the intestinal tract, reduce the loss of electrolyte and improve the health recovery of patients in the preparation process of the intestinal tract.
Detailed Description
The application will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present application and are not intended to limit the scope of the present application.
Example 1
The prescription of the composition comprises:
| composition components | Parts by weight of |
| Mannitol (mannitol) | 250 |
| L-arabinose | 30 |
| Vitamin C | 2 |
| Vitamin B6 | 1 |
| Calcium carbonate | 1.2 |
| Potassium chloride | 5 |
| Magnesium carbonate | 0.5 |
| Sodium chloride | 2 |
The weight parts are given in grams (g). Mannitol is mannitol aqueous solution with mass content of 20%.
Example 2
The prescription of the composition comprises:
| composition components | Parts by weight of |
| Mannitol (mannitol) | 125 |
| L-arabinose | 70 |
| Vitamin C | 1 |
| Vitamin B6 | 0.5 |
| Calcium carbonate | 0.3 |
| Potassium chloride | 1 |
| Magnesium carbonate | 5 |
| Sodium chloride | 2 |
The weight parts are given in grams (g). Mannitol is mannitol aqueous solution with mass content of 20%.
Example 3
The prescription of the composition comprises:
the weight parts are given in grams (g). Mannitol is mannitol aqueous solution with mass content of 20%.
Example 4
The prescription of the composition comprises:
| composition components | Parts by weight of |
| Mannitol (mannitol) | 150 |
| L-arabinose | 45 |
| Vitamin C | 2 |
| Vitamin B6 | 1 |
| Calcium carbonate | 0.6 |
| Potassium chloride | 3 |
| Magnesium carbonate | 2 |
| Sodium chloride | 6 |
The weight parts are given in grams (g). Mannitol is mannitol aqueous solution with mass content of 20%.
Example 5
The prescription of the composition comprises:
| composition components | Parts by weight of |
| Mannitol (mannitol) | 200 |
| L-arabinose | 60 |
| Vitamin C | 1 |
| Vitamin B6 | 0.5 |
| Calcium carbonate | 0.8 |
| Potassium chloride | 5 |
| Magnesium carbonate | 3 |
| Sodium chloride | 5 |
The weight parts are given in grams (g). Mannitol is mannitol aqueous solution with mass content of 20%.
Example 6
The prescription of the composition comprises:
| composition components | Parts by weight of |
| Mannitol (mannitol) | 180 |
| L-arabinose | 49 |
| Vitamin C | 2 |
| Vitamin B6 | 1 |
| Calcium carbonate | 0.7 |
| Potassium chloride | 4 |
| Magnesium carbonate | 2 |
| Sodium chloride | 6 |
The weight parts are given in grams (g). Mannitol is mannitol aqueous solution with mass content of 20%.
Case example 1
1. Basic information
46 patients receiving capsule endoscopy who were treated by the clinic of the people's hospitals in Shijia city from 10 months 2022 to 9 months 2023 were selected. All patients had no contraindications for enteroscopy. 46 patients were divided into a test group and a control group by a random number table method, wherein 22 test groups and 24 control groups, the test group received the composition of the present application, and the control group received polyethylene glycol 4000 powder. The test group had 10 men, 12 women, and an average age (45.64.+ -. 9.49) years. Control men were 11, women 13, and the average age (46.12.+ -. 10.48) years old. The two groups of patients had no statistical differences (P > 0.05) in baseline data of age, sex, etc.
2. Process and method
Two groups of patients had little grounds and half fluid food in 24 hours prior to the examination, restricted dietary fiber intake, and fasted after dinner the day prior to the examination. Test group: intestinal tract preparation was performed using the composition of example 6 of the present application, and the composition of example 6 of the present application was orally administered for 4 hours before examination, and 150-200ml of water was consumed after 10 minutes. Control group: the polyethylene glycol 4000 powder is taken before examination, 1L of polyethylene glycol 4000 powder is taken at night 1 day before examination, and 2L of polyethylene glycol 4000 powder is taken 4-6 hours before examination.
3. Efficacy evaluation index
1) Boston scale: the Boston scale scores the colon in 3 segments (cecum and ascending colon; liver, transverse and spleen, descending, sigmoid and rectum) with a score of 4 (0-3 points) according to worst-case score, total 0-9 points. (Table 1)
TABLE 1 Boston scale scoring criteria for intestinal preparation quality
| Scoring of | Description of the application |
| 0 point | The whole intestinal mucosa can not be observed due to the solid or liquid feces which can not be cleared |
| 1 minute | Part of the intestinal mucosa can not be observed due to dirty spots, turbid liquid and residual feces |
| 2 minutes | The intestinal mucosa is observed well, but a small amount of dirty spots, turbid liquid and feces remain |
| 3 minutes | The intestinal mucosa is observed well, and no residual dirty spots, turbid liquid and feces are basically generated |
2) Wortmawa scale: the wortmax scale scores the colon into 3 segments (rectum and sigmoid; transverse and descending; ascending and cecum) with a clear-to-differential score of 5 (0-4 points, table 2) and adds liquid volume scores (small, medium, large 0, 1, 2 points, respectively) to the whole colon, total score 0-14 points (table 2).
TABLE 2 wortmann scale scoring criteria for intestinal tract preparation quality
3) Electrolyte index: all enterally prepared patients were subjected to four serological examinations of electrolyte, including sodium serum, potassium serum, calcium serum, magnesium serum, and the number of electrolyte disorders was recorded.
4) Adverse reactions including nausea, vomiting, abdominal distension, etc. were evaluated.
4. Results
1) Boston scale comparison
The intestinal tract cleanliness is the worst in 0 and the best in 9, the Boston scale score of the test group is 7.67+/-1.65, the Boston scale score of the control group is 6.45+/-1.02, and the difference has statistical significance after statistical test, P is less than 0.05.
2) Comparison of wortmawa scale
Intestinal cleanliness was rated worst at 0 and best at 14, the wortmax rating of the test group was 13.07±1.58, the wortmax rating of the control group was 11.32±1.56, and the difference was statistically significant (P < 0.05).
3) Serum electrolyte conditions of different groups
The test group showed 11 cases of electrolyte disorder, 4 cases of hypokalemia, 4 cases of hyponatremia, 2 cases of hypocalcemia and 1 case of hypomagnesemia; the control group showed 21 cases of electrolyte disturbance, 8 cases of hypokalemia, 6 cases of hyponatremia, 4 cases of hypocalcemia, 3 cases of hypomagnesemia, and the difference was statistically significant (P < 0.05).
TABLE 3 electrolyte disturbance comparison
4) Adverse reaction comparison
Only 3 of the test groups showed gastrointestinal discomfort symptoms, 2 of them nausea and 1 abdominal distention; the control group showed 16 cases of gastrointestinal discomfort symptoms, 8 cases of nausea, 2 cases of vomiting, 6 cases of abdominal distension; the differences were statistically significant (P < 0.05) for both sets of comparisons.
Table 4 adverse reaction comparison
From the above results, it can be seen that: compared with the currently common intestinal tract preparation drug-polyethylene glycol 4000 powder, the application has better intestinal tract preparation effect before capsule endoscopy, less adverse reaction in the taking process, effectively improves the occurrence of electrolyte disorder caused by intestinal tract cleaning drugs, and has good clinical value.
Case example two
50 constipation sufferers who receive treatment from the medical hospitals of people in Shijia city are selected, and the ages are 10-71 years, wherein 23 women and 27 men.
The composition of the embodiment 1 of the application is taken before sleeping every day in the above cases, 150-200ml of water is drunk after 10min, 50 people constipation is obviously improved, and gastrointestinal symptoms such as nausea and vomiting are avoided in the taking process, so that the application can be used as a cathartic.
The present application is not limited to the above embodiments, but is capable of modification and variation in detail, and other modifications and variations can be made by those skilled in the art without departing from the scope of the present application.
Claims (7)
1. The composition used before capsule endoscopy is characterized by comprising the following raw material components in parts by weight: 125-250 parts of mannitol, 30-70 parts of L-arabinose, 1-2 parts of vitamin C, 0.5-1 part of vitamin B6, 0.3-1.2 parts of calcium carbonate, 1-10 parts of potassium chloride, 0.5-5 parts of magnesium carbonate and 2-10 parts of sodium chloride.
2. The composition for pre-capsule endoscopy of claim 1, wherein the composition comprises the following raw material components in parts by weight: 150-200 parts of mannitol, 45-60 parts of L-arabinose, 1-2 parts of vitamin C, 0.5-1 part of vitamin B6, 0.6-0.8 part of calcium carbonate, 3-5 parts of potassium chloride, 2-3 parts of magnesium carbonate and 5-6 parts of sodium chloride.
3. The composition for pre-capsule endoscopy of claim 1, wherein the composition comprises the following raw material components in parts by weight: 180 parts of mannitol, 49 parts of L-arabinose, 2 parts of vitamin C, 6 1 parts of vitamin B, 0.7 part of calcium carbonate, 4 parts of potassium chloride, 2 parts of magnesium carbonate and 6 parts of sodium chloride.
4. The composition for pre-capsule endoscopy of claim 1, wherein the mannitol is 20% mannitol by mass.
5. The composition for use before capsule endoscopy of claim 1, wherein the formulation of the composition is a liquid formulation or an oral formulation.
6. A pre-capsule endoscopy composition of claim 1, wherein the composition is for intestinal tract preparation; or as laxatives.
7. A pre-capsule endoscopic composition according to claim 1, further for preventing and/or treating nausea; preventing and/or treating emesis; preventing and/or treating abdominal distention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311149909.9A CN117100764A (en) | 2023-09-07 | 2023-09-07 | Composition used before capsule endoscopy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311149909.9A CN117100764A (en) | 2023-09-07 | 2023-09-07 | Composition used before capsule endoscopy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117100764A true CN117100764A (en) | 2023-11-24 |
Family
ID=88799986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311149909.9A Pending CN117100764A (en) | 2023-09-07 | 2023-09-07 | Composition used before capsule endoscopy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117100764A (en) |
-
2023
- 2023-09-07 CN CN202311149909.9A patent/CN117100764A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2584866T3 (en) | Purgative composition for the colon with soluble binding agent | |
| CN112089717B (en) | Application of arabinose and composition for preparing intestinal tract | |
| US9375441B2 (en) | Lactulose for bowel evacuation | |
| CN117100764A (en) | Composition used before capsule endoscopy | |
| JP2726165B2 (en) | Shampoo composition | |
| CN112315972B (en) | Composition for preparing intestinal tract | |
| ES2907081T3 (en) | Composition for the treatment of constipation | |
| AU2012202628B2 (en) | Colonic purgative composition with soluble binding agent | |
| Alexander | Systemic side effects with eye drops. | |
| JP2019043900A (en) | Agent for treating constipation which contains lactulose as an active ingredient | |
| ANDERS | TREATMENT OF THE GASTROINTESTINAL SYMPTOMS IN TYPHOID FEVER. | |
| BELLY | EUROMEDITERRANEAN BIOMEDICAL JOURNAL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |